Other
Antabio
is a France-based clinical-stage biopharmaceutical company that researches and develops novel antibacterial treatments for drug-resistant infections... Read moreAntabio
is a France-based clinical-stage biopharmaceutical company that researches and develops novel antibacterial treatments for drug-resistant infections... Read more2009
Labege
News
Sep 03, 2024
B3C Group
Press Release: Antabio : Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections
Dec 12, 2023
B3C Group
Press Release: Antabio : ANTABIO Raises 25 Million in Series B Financing
May 25, 2023
GlobalNewswire
Press Release: Antabio : Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections
May 06, 2020
FinanzNachrichten
Antabio: Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority Pathogens
Jan 05, 2020
Business Medical Dialogues
Antabio: Antabio gets USD 4.4 million funding to develop new treatment for Pseudomonas aeruginosa infections in CF patients
Jan 03, 2020
BioPortfolio
Antabio: Antabio SAS advances cystic fibrosis programme
Jan 02, 2020
The Pharma Letter
Antabio: Antabio awarded $4.4 million from CARB-X to fund development of its PEi
Aug 18, 2018
BioPortfolio
Antabio: Antabio SAS Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250
Jul 12, 2018
FinSMEs
Antabio: Biopharma Company Antabio Raises Additional €5.2M; Closes €12.5M Series A
Jan 15, 2018
PMLiVE
Antabio: Antabio bolsters leadership team
Antabio Competitors
1
2
3
4
5
6
7
8
9
10